Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Ca...( NEW YORK Feb. 13 /- Berkery Noyes...),Health
Navigation Links
Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC
Date:2/13/2008
NEW YORK, Feb. 13 /PRNewswire/ -- Berkery Noyes announced today that the firm represented The Riverside Company on the sale of its portfolio company HCPro Holdings, Inc. to Halyard Capital. The management team will continue to have an investment in the new entity. Terms of the transaction were not disclosed.
"This is an excellent match with Halyard Capital backing a veteran management team with a winning healthcare and information franchise," said Tom O'Connor, the Berkery Noyes Managing Director who managed the transaction on behalf of Riverside Company. "HCPro is a world class franchise in a growth segment of the ever expanding healthcare market," O'Connor added.
Berkery Noyes has been involved with many of the most notable transactions in the healthcare, pharmaceutical tools and services, and medical marketing sectors involving both strategic and financial buyers and sellers.
Berkery Noyes acted as The Riverside Company's exclusive financial advisor and represented it in its negotiations with Halyard Capital, LLC.
About Berkery Noyes
Berkery Noyes is one of the pre-eminent merger and acquisition firms serving the information industry, having completed more than 400 transactions since its inception. Among the most recent transactions completed by Berkery Noyes are the sale of Center Watch/NEIRB to Jobson Medical Information a portfolio company of The Wicks Group, HMP Communications to Alta Communications in partnership with Paul Mackler and Ken Fisher, the sale of Complete Healthcare Communications to MediMedia a portfolio company of Vestar Capital Partners, the divesture by The Thomson Corporation of American Health Consultants to Thompson Publishing Group; acquisition by Springer Science + Business Media of Current Medicine Group; acquisition by WebMd Corporation of Conceptis and the acquisition by The Wicks Group of DesignWrite, Inc..
Berkery Noyes' clients include private companies seeking a buyer, most
of the m
'/>"/>
| SOURCE Berkery Noyes Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Pulmonary Fibrosis Patients/9/11 Responders Represented at State of the Union Address for Second Year in a Row
2. Riverside First to Offer New Treatment for Peripheral Arterial Disease
3. Riverside Partners Teams with Management to Acquire GEMCITY Engineering & Manufacturing
4. Cogdell Spencer Announces a $100 Million Development at St. Lukes Riverside Outpatient Campus In Bethlehem, Pennsylvania
5. Susan G. Komen for the Cure, U.S. Congressman Pat Tiberi, Ohio Senator Tom Niehaus, and OhioHealth Riverside Breast Health Center Call for Action on Breast Cancer
6. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
7. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
8. Cleveland-based Health Care Tech Company Within3 Names New CEO
9. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
10. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
11. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
Post Your Comments:
(Date:11/30/2009)...y (EAU) and Europa Uomo, the European,advocacy mo... entered into an,affiliated partnership as part o...ve,patient awareness in Europe with regards to ur...sson, Secretary-General of the EAU: "Thanks to thi...will gain access to the latest information on,opt...
(Date:11/30/2009)...knows the enormous joy and comfort that an animal ...ts are considered important members of the family ...search now documents the value of the human-animal...llness, physical impairment, dementia, abuse and t...ated youth and adults. , In two articles in a re...
(Date:11/30/2009)...as launched a series of clinical trials in order t...t. This approach involves the application of perso...cells from the patient him or herself and designed...ve and frequent malignant tumours. The new therapy...d with the standard, first-line treatment involvin...
(Date:11/30/2009)...uot;My Two-Year Old Eats Octopus," gives meal...rything. , (PRWEB) Novemb...ouse? Do you find yourself acting as a short-orde... – one focusing on packing lunches, a second...l-life parents’ questions – introduce ...
(Date:11/30/2009)... so do knees, internal injuries, study finds, , ...you,re a middle-age weekend warrior who likes to h... A new study suggests that high levels of physical...hat could lead to osteoarthritis. , The study f...le who showed no symptoms and had a healthy weight...
Breaking Medicine News(10 mins):Health News:The therapeutic benefits of the human-animal bond 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:New Videos Help Parents of Picky Eaters 2Health News:New Videos Help Parents of Picky Eaters 3Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3[0] Affiliate partnership between EAU and Europa Uomo[0] The therapeutic benefits of the human-animal bond[0] Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines[0] New Videos Help Parents of Picky Eaters[0] Lots of Exercise in Midlife May Lead to Osteoarthritis
...) today announced third quarter and nine months re...ber 31, 2007, Hawkins reported sales,increased 30....ame period a,year ago. Net income for the quarter ...For the nine months ended December 31, 2007, Hawki...
...(Nasdaq: MLAB ) today announced that its Board of...ividend of ten cents per share of common,stock, pa...at the close of,business on February 25, 2008., M...ews release contains forward-looking statements wh...
... (both children and adults) when given gadolinium ... pre-medicated with corticosteroids and antihistam...earchers at the University of Michigan Health Syst...t agents, said Jonathan R. Dillman, MD, lead autho...
... Spending Cuts, ALEXANDRIA, Va., Feb. 8 Presiden...th programs vital to the future of,health and heal...on cut in,Medicaid, the nation,s single largest pa...end on, ranging from poison,control hotlines to fu...
....uk ), the,online ,front door, to the NHS, launche...sense of the stories appearing in the news about m...oices,( http://www.nhs.uk/News/Pages/NewsIndex.asp...g of the science. It,also provides an authoritativ...
...nger is suppressed , , FRIDAY, Feb. 8 (Hea...arriage is communication, and new research now not...tudy of Midwestern couples finds that those who fe...orst thing to do is to keep it in, not talk about ...
Other Medicine News:Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 2Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 3Health News:Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results 4Health News:Allergic-like reactions occur in premedicated patients 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 3Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 ResultsMesa Labs Declares Quarterly DividendAllergic-like reactions occur in premedicated patientsBush Budget Cuts Federal Health Programs Vital to the Health of All ChildrenNHS Choices Launches Medical News Guide to What Lies Behind the HeadlinesMutual Resentment in Marriage Can Be Deadly
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |